Eric R. Lutz

6.2k total citations · 1 hit paper
37 papers, 3.5k citations indexed

About

Eric R. Lutz is a scholar working on Oncology, Immunology and Biotechnology. According to data from OpenAlex, Eric R. Lutz has authored 37 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 24 papers in Immunology and 7 papers in Biotechnology. Recurrent topics in Eric R. Lutz's work include Cancer Immunotherapy and Biomarkers (22 papers), Immunotherapy and Immune Responses (21 papers) and Pancreatic and Hepatic Oncology Research (15 papers). Eric R. Lutz is often cited by papers focused on Cancer Immunotherapy and Biomarkers (22 papers), Immunotherapy and Immune Responses (21 papers) and Pancreatic and Hepatic Oncology Research (15 papers). Eric R. Lutz collaborates with scholars based in United States, Croatia and Italy. Eric R. Lutz's co-authors include Elizabeth M. Jaffee, Daniel A. Laheru, Mark Yarchoan, Burles A. Johnson, Sara Solt, Dung T. Le, Elizabeth A. Sugar, Beth Onners, Lei Zheng and Annie A. Wu and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Eric R. Lutz

35 papers receiving 3.5k citations

Hit Papers

Targeting neoantigens to augment antitumour immunity 2017 2026 2020 2023 2017 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Targeting neoantigens to augment antitumour immunity
    2017 727 citations Mark Yarchoan, Burles A. Johnson et al. Nature reviews. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric R. Lutz United States 15 2.6k 2.3k 673 307 298 37 3.5k
Jai Rautela Australia 19 1.0k 0.4× 1.3k 0.6× 648 1.0× 226 0.7× 136 0.5× 31 2.1k
Minal Barve United States 25 1.8k 0.7× 654 0.3× 1.3k 1.9× 444 1.4× 659 2.2× 179 2.9k
Johanna Olweus Norway 26 1.5k 0.6× 1.8k 0.8× 1.3k 2.0× 284 0.9× 241 0.8× 61 3.9k
Alena Gros Spain 28 4.3k 1.6× 3.6k 1.6× 1.5k 2.3× 307 1.0× 297 1.0× 54 5.6k
Sofia R. Gameiro United States 28 1.9k 0.7× 1.5k 0.7× 609 0.9× 208 0.7× 556 1.9× 59 2.7k
Todd D. Armstrong United States 29 2.0k 0.8× 2.3k 1.0× 843 1.3× 232 0.8× 230 0.8× 54 3.3k
Eleanor J. Cheadle United Kingdom 22 2.1k 0.8× 1.2k 0.5× 439 0.7× 88 0.3× 494 1.7× 35 2.7k
Jamie Honeychurch United Kingdom 21 1.9k 0.7× 1.4k 0.6× 396 0.6× 128 0.4× 639 2.1× 53 2.9k
Robbert van der Voort Netherlands 28 1.1k 0.4× 1.4k 0.6× 658 1.0× 110 0.4× 125 0.4× 43 2.4k
Simon J. Dovedi United Kingdom 24 2.0k 0.8× 1.4k 0.6× 416 0.6× 180 0.6× 578 1.9× 60 2.8k

Countries citing papers authored by Eric R. Lutz

Since Specialization
Citations

This map shows the geographic impact of Eric R. Lutz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric R. Lutz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric R. Lutz more than expected).

Fields of papers citing papers by Eric R. Lutz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric R. Lutz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric R. Lutz. The network helps show where Eric R. Lutz may publish in the future.

Co-authorship network of co-authors of Eric R. Lutz

This figure shows the co-authorship network connecting the top 25 collaborators of Eric R. Lutz. A scholar is included among the top collaborators of Eric R. Lutz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric R. Lutz. Eric R. Lutz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Lutz, Eric R., et al.. (2022). Abstract P2-14-07: Marrow-infiltrating lymphocytes as adoptive immunotherapy for breast cancer. Cancer Research. 82(4_Supplement). P2–14. 1 indexed citations
3.
Lutz, Eric R., Valentina Hoyos, Lakshmi Rudraraju, et al.. (2018). Marrow-Infiltrating Lymphocytes (MILs) Provide a Robust Platform for CAR-T Cell Therapy. Blood. 132(Supplement 1). 3337–3337. 3 indexed citations
4.
Hopkins, Alexander C., Eric R. Lutz, Annie A. Wu, et al.. (2018). Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. JCI Insight. 3(20). 132 indexed citations
5.
Hopkins, Alexander C., Mark Yarchoan, Jennifer N. Durham, et al.. (2018). T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. JCI Insight. 3(13). 175 indexed citations
6.
Yarchoan, Mark, Burles A. Johnson, Eric R. Lutz, Daniel A. Laheru, & Elizabeth M. Jaffee. (2017). Targeting neoantigens to augment antitumour immunity. Nature reviews. Cancer. 17(4). 209–222. 727 indexed citations breakdown →
7.
Noonan, Kimberly, Lakshmi Rudraraju, Valentina Hoyos, Eric R. Lutz, & Ivan Borrello. (2016). Persistence of Non Gene-Modified Adoptively Transferred Marrow Infiltrating Lymphocytes (MILs) More Than Five Years Post Transfer. Blood. 128(22). 4552–4552. 1 indexed citations
8.
Le, Dung T., Chan C. Whiting, Eric R. Lutz, et al.. (2016). Clinical and immune characteristics of rapid dropout and long-term survival in a phase II safety and efficacy study of combination CRS-207/GVAX immunotherapy in pancreatic cancer.. Journal of Clinical Oncology. 34(4_suppl). 459–459. 3 indexed citations
9.
Whiting, Chan C., Eric R. Lutz, Nitya Nair, et al.. (2015). Phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer: Clinical update on long term survival and biomarker correlates to overall survival.. Journal of Clinical Oncology. 33(3_suppl). 261–261. 9 indexed citations
10.
11.
Lutz, Eric R., Annie A. Wu, Elaine Bigelow, et al.. (2014). Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation. Cancer Immunology Research. 2(7). 616–631. 399 indexed citations
12.
Soares, Kevin C., Agnieszka A. Rucki, Annie A. Wu, et al.. (2014). PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors. Journal of Immunotherapy. 38(1). 1–11. 316 indexed citations
13.
Lutz, Eric R., et al.. (2014). Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. OncoImmunology. 3(11). e962401–e962401. 33 indexed citations
14.
Jaffee, Elizabeth M., et al.. (2014). Cancer Immunoprevention—The Next Frontier. Cancer Prevention Research. 7(11). 1072–1080. 19 indexed citations
15.
Le, Dung T., Eric R. Lutz, Jennifer N. Uram, et al.. (2013). Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer. Journal of Immunotherapy. 36(7). 382–389. 437 indexed citations
16.
17.
Laheru, Dan, Charles J. Yeo, Barbara Biedrzycki, et al.. (2007). A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas. Journal of Clinical Oncology. 25(18_suppl). 3010–3010. 15 indexed citations
18.
Murata, Satoshi, Brian H. Ladle, Peter Kim, et al.. (2006). OX40 Costimulation Synergizes with GM-CSF Whole-Cell Vaccination to Overcome Established CD8+ T Cell Tolerance to an Endogenous Tumor Antigen. The Journal of Immunology. 176(2). 974–983. 79 indexed citations
19.
Thomas, Amy, Eric R. Lutz, Todd D. Armstrong, et al.. (2004). Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients. The Journal of Experimental Medicine. 200(3). 297–306. 253 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jai Rautela Breakdown of academic impact, for papers by Minal Barve Breakdown of academic impact, for papers by Johanna Olweus Breakdown of academic impact, for papers by Alena Gros Breakdown of academic impact, for papers by Sofia R. Gameiro Breakdown of academic impact, for papers by Todd D. Armstrong Breakdown of academic impact, for papers by Eleanor J. Cheadle Breakdown of academic impact, for papers by Jamie Honeychurch Breakdown of academic impact, for papers by Robbert van der Voort Breakdown of academic impact, for papers by Simon J. Dovedi
Rankless by CCL
2026